Thermodynamics and Relative Solubility Prediction of Polymorphic Systems

Chemical Engineering in the Pharmaceutical Industry: R&D to Manufacturing

Volumn , Issue , 2010, Pages 477-490

  Abramov, Yuriy A ^a   Pencheva, Klimentina ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Application to likely impact on drug solubility estimation and unknown, more stable form; Qualification quantification of impact of form change on drug absorption; Thermodynamics and relative solubility prediction of polymorphic systems

Indexed keywords

EID: 84875228596     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470882221.ch25     Document Type: Chapter

References (53)

1. Brittain H.G.editor. Polymorphism in Pharmaceutical Solids, Marcel Dekker, New York 1999.
2. Burger A, Ramberger R. On the polymorphism of pharmaceuticals and other organic molecular crystals. I: theory of thermodynamic rules. Mikrochim Acta 1979; II: 259-271.
3. Grunenberg A, Henck J-O, Siesler HW. Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances. Int. J. Pharm. 1996; 129: 147-158.
4. Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G. Pharmaceutical solids: strategic approach to regulatory considerations. Pharm. Res. 1995; 12: 945-954.
5. Yu LX, Furness MS, RawA,Woodland OutlawKP, Nashed NE, Ramos E, Miller SPF, Adams RC, Fang F, Patel RM, Holcombe FO Jr., Chiu Y, Hussain AS. Scientific considerations of pharmaceutical solid polymorphs in abbreviated new drug applications. Pharm. Res. 2003; 20: 531-536.
6. Brittain HG, Grant DJW. Effects of polymorphism and solid-state solvation on solubility and dissolution rate. In: Brittain HG,editor, Polymorphism in Pharmaceutical Solids, Marcel Dekker, New York, 1999, pp. 279-330.
7. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, Wideburg NE, Saldivar A, Ruiz L, Kati WM, Sham HL, Robins T, Stewart KD, Hsu A, Plattner JJ, Leonard JM, Norbeck DW. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 2484-2488.
8. Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 2001; 18: 859-866.
9. Chemburkar SR, Bauer J, Deming K, Spiwek H, Patel K, Morris J, Henry R, Spanton S, Dziki W, Porter W, Quick J, Bauer P, Donaubauer J, Narayanan BA, Soldani M, Riley D, McFarland K. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Process Res. Dev. 2000; 4: 413-417.
10. Morissette SL, Soukasene S, Levinson D, Cima MG, Almarsson O. Elucidation of crystal form diversity of the HIV protease inhibitor Ritonavir by high-throughput crystallization. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 2180-2184.
11. Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J. Pharm. Sci. 2005; 94: 929-939.
12. Mao C, Pinal R, Morris KR. A quantitative model to evaluate solubility of polymorphs from their thermodynamic properties. Pharm. Res. 2005; 22: 1149-1157.
13. Grant DJW, Higuchi T, Solubility Behavior of Organic Compounds, Wiley, New York, 1990
14. Gu C-H, Grant DJW. Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J. Pharm. Sci. 2001; 90: 1277-1287.
15. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 2000; 17: 397-403.
16. Hildebrand JH, Scott RL. Regular Solutions, Prentice-Hall, Englewood Cliffs, NJ, 1962.
17. MishraDS,YalkowskySH. Idealsolubilityofasolidsolute:effect of heat capacity assumptions. Pharm. Res. 1992; 9: 958-959.
18. Neau SH, Flynn GL. Solid and liquid heat capacities of n-alkyl para-aminobenzoates near the melting point. Pharm. Res. 1990; 7: 1157-1162.
19. Neau SH, Flynn GL, Yalkowsky SH. The influence of heat capacity assumptions on the estimation of solubility parameters from solubility data. Int. J. Pharm. 1989; 49: 223-229.
20. Neau SH, Bhandarkar SV, Hellmuth EW. Differential molar heat capacity to test ideal solubility estimations. Pharm. Res. 1997; 14: 601-605.
21. Pappa GD, Voutsas EC, Magoulas K, Tassios DP. Estimation of the differential molar heat capacities of organic compounds at their melting point. Ind. Eng. Chem. Res. 2005; 44: 3799-3806.
22. Hoffman JD. Thermodynamic driving force in nucleation and growth processes. J. Chem. Phys. 1958; 29: 1192-1193.
23. Gracin S, Brinck T, Rasmuson AC. Prediction of solubility of solid organic compounds in solvents by UNIFAC. Ind. Eng. Chem. Res. 2002; 41: 5114-5124.
24. Hojjati H, Rohani S. Measurement and prediction of solubility of paracetamol in water-isopropanol solution. Part 2. Prediction. Org. Process Res. Dev. 2006; 10: 1110-1118.
25. Defossemont G, Randzio SL, Legendre B. Contributions of calorimetry for Cp determination and of scanning transitiometry for the study of polymorphism. Cryst. Grow. Des. 2004; 4: 1169-1174.
26. Higuchi WI, Lau PK, Higuchi T, Shell JW. Solubility relationship in the methylprednisolone system. J. Pharm. Sci. 1963; 52: 150-153.
27. Yu L. Inferring thermodynamic stability relationship of polymorphs from melting data. J. Pharm. Sci. 1995; 84: 966-974.
28. Aguiar AJ, Krc J. Jr., Kinkel AW, Samyn JC. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. J. Pharm. Sci. 1967; 56: 847-853.
29. Rowe EL, Anderson BD. Thermodynamic studies of tolbutamide polymorphs. J. Pharm. Sci. 1984; 73: 1673-1675.
30. Ghodbane S, McCauley JA. Study of the polymorphism of 3-(((3-(2-(7-chloro-2-quinolinyl)-(E)-ethenyl)phenyl)((3-(dimethylamino-3-oxopropyl)thio)methyl)-thio)propanoic acid (MK571) by DSC, TG, XRPD and solubility measurements. Int. J. Pharm. 1990; 59: 281-286.
31. Gerber JJ, vanderWatt JG, Lötter AP. Physical characterization of solid forms of cyclopenthiazide. Int. J. Pharm. 1991; 73: 137-145.
32. Kushida I, Ashizawa K. Solid state characterization of E2101, a novel antispastic drug. J. Pharm. Sci. 2002; 91: 2193-2202.
33. Rollinger JM, Gstrein EM, Burger A. Crystal forms of torasemide: newinsights. Eur. J. Pharm. Biopharm. 2002; 53: 75-86.
34. ShibataM,Kokubo H, Morimoto K, Morisaka K, IshidaT, Inoue M. X-ray structural studies and physicochemical properties of cimetidine polymorphs. J. Pharm. Sci. 1983; 72: 1436-1442.
35. Crafts PA. The role of solubility modelling and crystallization in the design of active pharmaceutical ingredients. In: Ng KM, Gani R, Dam-Johansen K, editors, Chemical Product Design: Toward a Perspective through Case Studies, Elsevier, Dordrecht, The Netherlands, 2007, pp. 23-85.
36. Ye Q, Hart RM, Kania R, Ouellette M, Wu ZP, Zook SE. Polymorphic forms of 6-[2-(-(methylcarbomoyl) phenylsulfanyl]-3-E-[2-pyridin-2-yl)ethenyl]indazole. U.S. Patent 0094763, 2006.
37. Campeta AM, Chekal BP, McLaughlin RW, Singer RA. Novel crystalline forms of a VEGF-R inhibitor. PCT Int. Appl. 2008; WO 2008122858.
38. Chekal B, Campeta AM, Abramov YA, Feeder N, Glynn P, McLaughlin R, Meenan P, Singer R. Facing the challenges of developing an API crystallization process for a complex polymorphic and highly-solvating system. Part I. Org. Process Res. Dev. 2009; 13: 1327-1337.
39. Sohn YT. Study on the polymorphism of acetaminophen. J. Korean Pharm. Sci. 1990; 20: 97-104.
40. Sheikhzadeh M, Rohani S, Traffish M, Murad S. Solubility analysis of buspirone hydrochloride polymorphs: measurements and prediction. Int. J. Pharm. 2007; 338: 55-63.
41. Behme RL, Brooke D. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. J. Pharm. Sci. 1990; 80: 986-990.
42. Behme RJ, Brooke D, Farney RF, Kensler TT. Research article characterization of polymorphism of gepirone hydrochloride. J. Pharm. Sci. 1985; 74: 1041-1046.
43. Collman B, private communication
44. Vrečer F, Vrbinc M, Meden A. Characterization of piroxicam crystal modifications. Int. J. Pharm. 2003; 256: 3-15.
45. BartolomeiM,Bertocchi P, RamusinoMC,Santucci N,Valvo L. Physico-chemical characterization of the modifications I and II of (R, S) propranolol hydrochloride: solubility and dissolution. J. Pharm. Biomed. Anal. 1999; 21: 299-309.
46. Caviglioli C, Pani M, Gatti P, Parodi B, Cafaggi S, Bignargi G. Study of retinoic acid polymorphism. J. Pharm. Sci. 2006; 95: 2207-2221.
47. Carlton RA, Difeo TJ, Powner TH, Santos I, Thompson MD. Preparation and characterization of polymorphs for an LTD4 antagonist, RG 12525. J. Pharm. Sci. 1996; 85: 461-467.
48. Rocco WL, Swanson JR. WIN 63843 polymorphs: prediction of enantiotropy. Int. J. Pharm. 1995; 117: 231-236.
49. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Del. Rev. 2004; 56: 335-347.
50. Amidon GL, Lennernas H, Shah VP, Crison JRA. Theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995; 12: 413-420.
51. Varma MVS, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J. Med. Chem. 2010; 53: 1098-1108.
52. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 2004; 1: 85-96.
53. Taylor JR. An Introduction to Error Analysis. University Science Books, Mill Valley, CA, 1982.